Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 3 | 2 |
| Executive Summary | 5 | 1 |
| Market Landscape Poised for Entry of Novel Products | 5 | 1 |
| Moderately-Sized but Strong First-in-Class Pipeline | 5 | 1 |
| Strong Uptake of First-in-Class Products in Strategic Consolidations | 5 | 1 |
| The Case for Innovation | 6 | 3 |
| Growing Opportunities for Biologic Products | 7 | 1 |
| Diversification of Molecular Targets | 7 | 1 |
| Innovative First-in-Class Product Development Remains Attractive | 7 | 1 |
| Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation | 8 | 1 |
| Sustained Innovation | 8 | 1 |
| Clinical and Commercial Landscape | 9 | 13 |
| Therapy Area Overview | 9 | 1 |
| Glaucoma | 9 | 1 |
| Age-related Macular Degeneration | 9 | 1 |
| Diabetic Macular Edema | 9 | 1 |
| Diabetic Retinopathy | 9 | 1 |
| Dry Eye Syndrome | 10 | 1 |
| Disease Symptoms | 10 | 2 |
| Epidemiology and Etiology | 12 | 1 |
| Glaucoma | 12 | 1 |
| Age-related Macular Degeneration | 12 | 1 |
| Diabetic Retinopathy and Diabetic Macular Edema | 12 | 1 |
| Dry Eye Syndrome | 12 | 1 |
| Diagnosis | 13 | 1 |
| Pathophysiology | 13 | 1 |
| Healthy Eye Physiology | 13 | 1 |
| Glaucoma | 14 | 1 |
| Age-related Macular Edema | 15 | 1 |
| Diabetic Macular Edema and Diabetic Retinopathy | 16 | 1 |
| Treatment Options | 17 | 2 |
| Prognosis | 19 | 1 |
| Glaucoma | 19 | 1 |
| Age-Related Macular Degeneration | 19 | 1 |
| Diabetic Retinopathy and Diabetic Macular Edema | 19 | 1 |
| Dry Eye Syndrome | 20 | 1 |
| Overview of Marketed Products in Ophthalmology | 20 | 1 |
| Molecule Type and Target Analysis | 20 | 2 |
| Assessment of Pipeline Product Innovation | 22 | 13 |
| Ophthalmology Pipeline by Molecular Target | 25 | 3 |
| Comparative Distribution of Programs between the Ophthalmology Market and Pipeline by Therapeutic Target Family | 28 | 1 |
| First-in-Class Pipeline Programs Targeting Novel Molecular Targets | 28 | 7 |
| Signaling Network, Disease Causation and Innovation Alignment | 35 | 4 |
| Complexity of Signaling Networks in Ophthalmology | 35 | 1 |
| First-in-Class Matrix Assessment | 35 | 4 |
| First-in-Class Target Evaluation | 39 | 11 |
| Pipeline Programs Targeting RPE65 and RBP4 | 39 | 2 |
| Pipeline Programs Targeting Eotaxin-1 and CCR3 | 41 | 2 |
| Pipeline Programs Targeting LRP6 | 43 | 1 |
| Pipeline Programs Targeting TGF-Beta 2 | 44 | 1 |
| Pipeline Programs Targeting NGF, and LNGFR and TrkA Nerve Growth Factor Receptors | 45 | 3 |
| Pipeline Programs Targeting Serine Protease HtrA1 | 48 | 1 |
| Conclusion | 49 | 1 |
| Deals and Strategic Consolidations | 50 | 13 |
| Industry-Wide First-in-Class Deals | 50 | 1 |
| Licensing Deals | 51 | 2 |
| Licensing Deals by Molecule Type | 53 | 1 |
| Licensing Deals by Molecular Target | 53 | 2 |
| Licensing Deals Valued Above $100m | 55 | 1 |
| Co-development Deals | 56 | 1 |
| Co-development Deals by Molecule Type | 57 | 1 |
| Co-development Deals by Molecular Target | 57 | 2 |
| Co-development Deals Valued Above $100m | 59 | 1 |
| First-in-Class Programs Not Involved in Licensing or Co-development Deals | 60 | 3 |
| Appendix | 63 | 8 |
| Abbreviations | 63 | 1 |
| References | 63 | 5 |
| Research Methodology | 68 | 1 |
| Secondary Research | 69 | 2 |
| Market Analysis | 69 | 1 |
| Pipeline Analysis | 69 | 1 |
| Overall Pipeline | 69 | 1 |
| First-in-Class Analysis | 69 | 1 |
| First-in-Class Matrix Assessment | 69 | 1 |
| First-in-Class Target Profiles | 70 | 1 |
| Licensing and Co-development Deals | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 70 | 1 |